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Abstract
Background: The pathogenesis of progressive renal insufficiency in autosomal dominant polycystic kidney disease
(ADPKD) is unclear. Evidence from experimental models of ADPKD suggests that elevated endothelin-1 (ET-1) drives
cyst growth, renal fibrosis and loss of renal function, but whether ET-1 is elevated in humans with ADPKD is uncertain.
Methods: In a cross-sectional study of ADPKD we measured urinary ET-1, a surrogate for ET-1 in kidney cortex, in
spot collections corrected for creatinine. The volume of each kidney was measured using MRI-based stereology.
The relationship of urine ET-1 with MDRD eGFR and kidney volume was modeled by multiple linear regression
with adjustment for clinical covariates.
Results: Patients with ADPKD were ages 18 to 53 with eGFRs (median, interquartile range) of 63.2 (43.5–80.2)
ml/min/1.73 m2 and albumin/creatinine ratios (ACR) of 115.0 (7.5–58.5) μg/mg. Urine ET-1 was inversely associated
with eGFR (r = −0.480, P < 0.05) and positively (r = 0.407, P = 0.066) with ACR independent of age and female sex
(P < 0.01). ET-1 appeared to be positively associated with total kidney volume (r = 0.426, P = 0.100), with a test for
trend across urine ET-1 quartiles yielding z = 1.83, P = 0.068. ET-1 strongly correlated with NAGase (r = 0. 687, P =
0.001), a marker of tubular damage and a surrogate marker of renal disease progression in ADPKD. Of note, ET-1
levels in urine were not correlated with hypertension.
Conclusions: In a translational study of patients with ADPKD, urinary ET-1 was inversely associated with eGFR
and positively correlated with total kidney volume. Taken together with results from experimental models, these
findings suggest that the role of ET-1 in ADPKD warrants further investigation.
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Background
Autosomal dominant polycystic kidney disease (ADPKD)
is the most prevalent inherited form of kidney disease
and the fourth leading cause of end-stage renal disease
(ESRD) in the US [1, 2]. ADPKD occurs in one of every
400 live births and is characterized by bilateral, progres-
sive enlargement of focal cysts in all nephron segments.
Onset and morbidity often occurs in children and ado-
lescents and leads to numerous complications including
hypertension, pain, hematuria, proteinuria, kidney stones
and declining renal function. Direct medical costs for
dialysis and transplantation to treat ADPKD are esti-
mated at 1.5 billion U.S. dollars per year [2]. Current
therapies are directed at controlling hypertension, pain
and the complications of chronic kidney disease but do
not prevent progression of ADPKD [3].
Endothelin-1 (ET-1), an endothelium-derived vasocon-
strictor and pro-fibrotic peptide [4–6], has emerged as a
possible therapeutic target for inhibiting cyst growth and
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interstitial fibrosis in ADPKD. Transgenic overexpres-
sion of ET-1 in mice causes extensive cyst formation in
the kidney with glomerular and peritubular fibrosis and
monocyte infiltration without increasing blood pressure
[7]. Renal expression of ET-1 is robustly elevated in
murine and rat models of PKD and is associated with
cyst formation and the development of hypertension
[8–10]. In humans with ADPKD, immunoreactive ET-1
has been localized in cyst epithelia, mesangial cells and
vascular smooth muscle cells [11]. Compared to healthy
age-matched controls, ETA mRNA is 5-10-fold higher
in ADPKD cystic kidneys. In a small cohort of patients
with all forms of PKD (n = 20, ESCAPE Trial Group),
urine ET-1 excretion was elevated compared to control
subjects without chronic kidney disease [12].
Synthesis of ET-1 by kidney cells is the primary
source of urinary ET-1; < 1.0 % of ET-1 in urine derives
from the filtered load [13–17]. Thus urinary ET- is a
non-invasive surrogate for ET-1 in kidney tissue that
avoids the risk and cost associated with immunohisto-
chemical analysis in percutaneous renal biopsy. Here,
we investigated the hypothesis that elevated levels of
urine ET-1 are associated with decreased eGFR and in-




This was a cross-sectional study of 21 ADPKD outpa-
tients recruited between April 2013 and February 2014
at University Hospitals Case Medical Center (Additional
file 1). Studies were approved by the Institutional Review
Board at University Hospitals Case Medical Center, and
informed consent was obtained from all participants.
Eligibility criteria included diagnosis of ADPKD by the
Modified Ravine Unified Criteria [18] and eGFR ≥ 15 ml/
min/1.73 m2 estimated by the MDRD formula [19]. Pa-
tients were diagnosed with ADPKD if radiographic im-
aging demonstrated at least two renal cysts in the setting
of a family history of ADPKD, or in families of unknown
genotype, the presence of three or more renal cysts (in
individuals between 15 and 39 years old), or two or more
cysts in each kidney (in individuals between 40 and
59 years old). Exclusion criteria included unwillingness
or inability to provide informed consent, pregnancy,
lactation, and current substance abuse. We also recruited
seven age- and sex-matched controls without apparent
kidney disease. All data were obtained at the study visit or
from the paper or electronic medical record. Blood pres-
sure was averaged from three consecutive measurements
(1 min between readings), with the patient seated using
an automated oscillometric device (Omron HEM-907).
Hypertension was defined as systolic BP ≥ 140 mmHg,
diastolic BP ≥ 90 mmHg, or use of antihypertensive
medications (thiazide diuretics, β-blockers, calcium chan-
nel blockers, angiotensin-converting enzyme inhibitors,
angiotensin type 2 receptor blockers). Polycystic liver
disease in patients with ADPKD was defined as the
presence of ≥ 4 cysts on MRI or ultrasound [20].
Urine collection and processing
Trained personnel obtained random spot urine speci-
mens (∼40 ml midstream) at study visits. Aliquots of
urine were sent to the University Hospitals Case Medical
Center central laboratory for measurement of urine al-
bumin and creatinine. Remaining urine (~30 ml) was
processed as described by the Human Kidney and Urine
Proteome Project and the European Urine and Kidney
Proteomics Initiative [21]. After conventional urine dip-
stick analysis (Multistix 8 SG, Bayer, Tarrytown, NY),
the specimen was transferred to a 50-ml conical tube
and centrifuged at 1500 × g for 10 min in a refrigerated
centrifuge to pellet cells. Smaller aliquots (10 ml) were
centrifuged at 10,000 × g to remove particulates and ali-
quoted for storage at −80 °C. Processed samples were
frozen within 3 h of collection. Before analysis, urine
pH was adjusted to 8.0 with 1 M Tris buffer (pH 8.0) to
help solubilize aggregates that may form after thawing.
Assays were performed within 4 months of urine col-
lection after no more than 1 freeze-thaw cycle.
Measurements of total kidney volume
Magnetic resonance imaging studies were performed
as previously reported by Chapman et al. in the CRISP
study of ADPKD [22]. Briefly, we obtained coronal
T2-weighted images and gadolinium-enhanced three-
dimensional volume-interpolated spoiled-gradient echo
coronal T1-weighted images (3-mm slice thickness). Kid-
ney volumes were measured in T1-weighted images by
stereology estimated from contiguous images by summing
the products of the area measurements and slice thick-
ness. Reliability coefficients were 0.972 for TKV in re-
peatedly acquired images on individual patients. The
average coefficients of variation of TKV is estimated to
be 0.01 [23].
Sandwich enzyme-linked immunosorbent assay of
human ET-1
Urinary ET-1 was measured in duplicate by ELISA
(R&D Systems, Minneapolis, MN) as previously reported
[17]. Mean ET-1 concentration was normalized for urine
creatinine measured by the University Hospitals Case
Medical Center central laboratory. Urine aliquots for
measurement of ET-1 were extracted in acetic acid exactly
as described [24]. The intra- and interassay coefficient of
variation was equal to or less than the manufacturer-
reported values in human urine. Laboratory personnel
were blinded. Biological variation in urine ET-1 excretion
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in ADPKD participants was calculated in ten randomly se-
lected participants with three serial measurements over
24 weeks as the intra-(CVI) and inter-individual (CVG) co-
efficient of variation as described by Fraser [25].
Urinary excretion of NAGase
N-acetyl-β-D-glucosaminidase (NAGase) is a 130-kD
glycolytic lysosomal enzyme localized mainly in prox-
imal tubules and shed into urine upon cell injury in a
variety of kidney diseases [26, 27]. We measured urine
NAGase using the substrate 2-methoxy-4-(2-nitrovinyl)
phenyl-glucosaminide and bovine NAGase as a cali-
brant according to the manufacturers’ protocols (PPR
Diagnostics, London). NAGase values were corrected
for urine creatinine. The intraassay and interassay coef-
ficients of variation were 8.3 and 12.3 %, respectively.
Statistical analysis
Continuous variables are presented as median and inter-
quartile range (IQR) and proportions for categorical var-
iables. Normality was assessed by visual inspection and
the Shapiro-Wilk test, P > 0.05. The distribution of urine
ET-1 was highly skewed leftward, so analyses were per-
formed on log-transformed data. Pearson correlation of
urine ET-1 with MDRD eGFR and total kidney volume
are presented. Median total kidney volume was com-
pared across quartiles of urine ET-1 using the test for
trend across ordered groups described by Cuzick [28].
The association of urine ET-1 with eGFR and ACR was
assessed in multiple variable linear regression models
that included age and sex as potential confounders. Data
analysis was performed by the authors (LL, AS-D, and
MSS) using Stata 13.0 (Stata, College Station Texas,
United States).
Results
Twenty-one participants were recruited with median
age of 39.2 years; 29 % were female (Table 1). Median
eGFR was 63.2 ml/min/1.73 m2 and albumin to creatin-
ine ratio was 115 μg/mg. Values for systolic blood pres-
sure were under 140 mm Hg with a median of 123 mm
Hg (Table 1). Twenty-two percent of participants had
polycystic liver disease, and 82 % were taking renin
angiotensin system inhibitors or Tolvaptan (Table 1).
Correlation of urine ET-1 with eGFR
Urine ET-1 was elevated in participants with ADPKD
compared to age- and sex-matched controls with with-
out apparent kidney disease (mean ± SD, 4.1 ± 2.9 versus
1.3 ± 0.9 ng/mg creatinine, P < 0.01). In participants with
ADPKD, urine ET-1 was associated with lower eGFR. A
Pearson’s product–moment correlation was run to assess
the relationship between urine ET-1 and eGFR. Prelim-
inary analysis showed the relationship to be linear with
log transformed urine ET-1 normally distributed as
assessed by the Shapiro-Wilk test (P < 0.05). As shown in
Fig. 1, there was a moderate inverse correlation, r = −0.480,
P = 0.026, with urine ET-1 explaining 25 % of the vari-
ation in eGFR. The biological variation of urine ET-1
excretion in ADPKD participants was assessed in ten
randomly selected participants with three serial mea-
surements over 24 weeks. The intra- individual coeffi-
cient of variation (CVI) was 12.8 % and inter-individual
coefficient of variation (CVG) was 14.6 %, making it un-
likely that natural variation in ET-1 excretion does not
account for the magnitude of the inverse association of
urine ET-1 with eGFR [25]. ET-1 correlated with log al-
buminuria, r = 0.407, but did not quite reach statistical
significance at P = 0.066. Interestingly, urine ET-1 did
not correlate with systolic or diastolic blood pressure.
Table 1 Clinical characteristics of the cross-sectional sample of




eGFR, ml/min/1.73 m2 63.2 (43.5–80.2)
Urine Albumin/Creatinine Ratio, μg/mg 115.0 (7.5–58.5)
Total Kidney Volume, ml 1270 (839–1545)
Systolic Blood Pressure, mm Hg 123 (110–138)
Diastolic Blood Pressure, mm Hg 88 (79–98)
Polycystic Liver Disease (%) 22
Renin Angiotensin System Inhibitors (%) 82
Tolvaptan (%) 82
aIQR interquartile range
Fig. 1 Urine ET-1 inversely correlated with eGFR in a cross-sectional
analysis of 21 patients with ADPKD. ET-1 was measured by ELISA in
spot urine specimens and values were adjusted for urine creatinine.
Because the distribution of urine ET-1 was non-normal, log-transformed
values were utilized
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A multiple linear regression was run to test for pos-
sible confounding between urine ET-1 and eGFR or
ACR by age and sex. The assumptions of linearity, inde-
pendence of errors and normality of residuals were
met. The variables statistically significantly predicted
eGFR, F(3,16) = 4.90, P = 0.013, adjusted R2 = 0.38. Only
urine ET-1 and age added statistically significantly to
prediction of eGFR, P < 0.05. However, the contribution
of age was modest, as demonstrated by the regression
coefficients and standard errors (Table 2). Holding
urine ET-1 and sex constant, eGFR is predicted to de-
crease by 1.0 ml/min/1.73 m2 when age increases by
1 year, whereas holding age and sex constant, eGFR is
predicted to decrease 5.4 ml/min/1.73 m2 for every
1 ng/mg increment in urine ET-1. In separate regres-
sion models the regression of eGFR on urine ET-1 was
not statistically significantly affected by treatment with
renin angiotensin system inhibitors or Tolvaptan (data
not shown). Similarly, there was a small but statistically
significant effect of age on prediction of ACR (Table 2),
and no statistically significant effect of renin angioten-
sin system inhibitors or Tolvaptan.
Urine NAGase and ET-1 levels
Damage to the structure and function of tubular epithe-
lial cells characterizes ADPKD and often precedes the
decline in GFR [1]. Therefore, we examined the correl-
ation urine NAGase, an index of tubular damage [27],
with ET-1 excretion. ET-1 strongly correlated with
NAGase (r = 0. 687, P = 0.001). Urine NAGase was mod-
erately and inversely associated with eGFR (r = −0.551,
P = 0.001) and strongly with total kidney volume (r =
0.728, P = 0.001).
Urine ET-1 and total kidney volume
Total kidney volume at baseline predicts risk of develop-
ing renal insufficiency [23], and in our study there was a
trend towards lower eGFR in patients with higher total
kidney volume, r = −0.289, P = 0.278. Because ET-1 stim-
ulates cyst formation and growth in animal models, we
examined the relationship of urine ET-1 with total kid-
ney volume, an index of cyst growth. Higher levels of
urine ET-1 were correlated with increased total kidney
volume in patients with ADPKD (Fig. 2). There was a
moderate positive correlation of urine ET-1 with total
kidney volume, r = 0.426, that did not attain statistical
significance, P = 0.100, with ET-1 explaining 16 % of the
variation in total kidney volume. To further evaluate
the relationship between urine ET-1 and total kidney
volume, we tested for trend (Fig. 3). Testing for trend
using a nonparametric test across quartiles yielded z =
1.83, P = 0.068.
Discussion
Abundant preclinical data suggest that elevated ET-1
promotes cyst growth and renal fibrosis in ADPKD
[7–10]. Here we report that increased ET-1 was associ-
ated with decreased eGFR and may be correlated with
Table 2 Summary of multiple linear regression model of ET-1,
age and sex to predict eGFR and ACR in patients with ADPKD
eGFR ACR
Variable B SEB Π B SEB P
Urine ET-1 −5.366 2.910 0.084 104.9 36.1 0.023
Age −1.017 0.388 0.019 −14.7 6.1 0.041
Sex 8.978 12.541 0.484 −118.2 152.7 0.461
Note: * P < 0.05; B unstandardized regression coefficient, SEB standard error of B.
Overall P for both models is P < 0.01
Fig. 2 Positive correlation of urine ET-1 with total kidney volume.
The log transform of urine ET-1 measured in spot urine specimens
was plotted versus total kidney volume, r = 0.426, that did not attain
statistical significance, P = 0.100. Identical results were obtained
when TKV was referenced to participant height
Fig. 3 Total kidney volume trended higher across quartiles of urine
ET-1. Each box represents the 25th to 75th percentile, and the line
represents the median total kidney volume within a given quartile
of log urine ET-1. There was a trend towards higher total kidney
volume as urine ET-1 increased, z = 1.83, P = 0.068
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elevated TKV in patients with ADPKD. ET-1 corre-
lated with a marker of tubular damage in ADPKD,
NAGase, but not with systolic or diastolic blood pressure.
Taken together with data from experimental models, these
results support the hypothesis that ET-1 is elevated in pa-
tients with ADPKD is association with renal insufficiency.
Grenda et al. [12] reported a 1.6-fold increase in urin-
ary ET-1 excretion compared to controls in 20 children
(age 10.2 ± 3.6 years) with polycystic kidney disease. In
the present study, we significantly expand on these re-
sults by showing that urine ET-1 is elevated 3.2-fold in
adults with ADPKD compared to age- and gender-
matched controls. Urinary excretion of ET-1 in ADPKD
was significantly and negatively associated with eGFR
(r = −0.480, P = 0.026), and appeared to be positively asso-
ciated with increased excretion of urine albumin, consist-
ent with a role in progressive renal injury and dysfunction.
Of note, urine ET-1 did not correlate with hypertension,
which further supports results in experimental models
demonstrating a blood pressure-independent action of
ET-1 in the pathogenesis of ADPKD [7, 10].
Elevated ET-1 has correlated with scarring and chronic
disease in a variety of preclinical models of kidney dis-
ease [10, 11, 29, 30], thus we asked whether ET-1 corre-
lates with urine NAGase in ADPKD. ET-1 correlated
strongly with NAGase (r = 0. 687, P = 0.001). These find-
ings may be significant because ADPKD is characterized
histologically by injury to tubules that often precedes a
decline in GFR [1]. NAGase, distributed mainly in lyso-
zymes of the proximal tubule and cyst-lining epithelial
cells in ADPKD patients [26, 31], is shed into urine
upon damage to tubular epithelial cells [27]. In a cross-
sectional analysis, urine NAGase was 7.8-fold higher in
102 participants with ADPKD compared to 102 age-
and sex-matched healthy controls [32]. Moreover, urine
NAGase predicted patients with progressive decline of
GFR (area under the receiver operating characteristic
curve = 0.794) in a 1-year prospective cohort study of
270 patients with ADPKD [31]. Consistent with previ-
ous studies by Meijer et al. [32] and Park et al. [31], we
also observed that NAGase correlated inversely with
eGFR and positively with total kidney volume. Collect-
ively, these data are consistent with a role for ET-1 as a
mediator of tubular damage in ADPKD.
Progression of ADPKD stems primarily from forma-
tion and growth of renal cysts [33, 34]. Cyst formation,
due to localized epithelial cell proliferation, results in
renal function decline secondary to obstruction of the
tubules in which cysts grow. Cyst growth is also thought
to be responsible for subsequent upstream blockage,
downstream tubular atrophy and, eventually, glomerulo-
sclerosis. Thus, while cyst formation is an early indicator
of disease progression, in the later stages, fibrosis is the
dominant factor for renal decline [34]. Current therapies
are directed at controlling hypertension, pain and the
complications of chronic kidney disease but do not pre-
vent progression of ADPKD [3]. In addition, standard
measures of renal disease progression, including esti-
mated or measured glomerular filtration rates (GFR),
do not show changes until significant damage has oc-
curred. Thus, there is an urgent need for non-invasive
biomarkers to identify ADPKD patients at high risk for
progression before significant renal insufficiency oc-
curs. Those patients, at an early stage of disease, could
then be targeted for therapies as new approaches
emerge. It is also possible that ET-1 may be a thera-
peutic target in ADPKD. In a previous study, an ETB
receptor antagonist (A-192621) accelerated disease pro-
gression in a murine model of ADPKD [35]. However,
recent studies demonstrate differential effects of ETA
and ETB receptors in progression of kidney disease and
favor a reno-protective effect of ETA receptor antago-
nists [36], so studies are necessary to determine efficacy
of ET-1 receptor blockers in ADPKD.
Conclusions
Urine ET-1 is associated inversely with eGFR independ-
ent of age, sex and blood pressure in a pilot, cross-
sectional study. Potential significance of our findings are
that ET-1 may be a novel therapeutic target for slowing
progression of kidney disease in ADPKD. Development
of orally-active receptor antagonists for ETA and/or ETB
receptor is in early stages, but these drugs have been
approved recently for treatment of pulmonary artery
hypertension and scleroderma-related digital ulcers.
Multiple clinical studies point to efficacy of ETA recep-
tor antagonists in diabetic and non-diabetic chronic
kidney disease [37, 38]. To our knowledge ETA or ETB
antagonists have not been studied in trials of ADPKD.
Another possibility is that elevated urinary excretion of
ET-1 may be a biomarker of early renal injury. Our
findings suggest that additional studies of ET-1 and ET-
1 receptor antagonists in ADPKD, particularly longitu-
dinal trials, may be warranted.
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